Anthony Fauci, AP Images

Gilead — Piv­otal Covid-19 study of remde­sivir ‘met its pri­ma­ry end­point,' is emer­gency au­tho­riza­tion next?

Gilead has de­clared a huge vic­to­ry in the war against Covid-19.

In a short state­ment, the big biotech said that the piv­otal, con­trolled study of remde­sivir at the Na­tion­al In­sti­tute of Al­ler­gy and In­fec­tious Dis­eases had met its pri­ma­ry end­point. This was one of the key clin­i­cal hur­dles set up by NI­AID chief An­tho­ny Fau­ci.

Gilead $GILD in­clud­ed no da­ta in their state­ment, but said that NI­AID is plan­ning to sketch out the pos­i­tive re­sults in an up­com­ing brief­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.